PepTrackevidence-graded reference
Development trackerPipeline
Development tracker

Pipeline

Where each compound actually sits — from FDA-approved drugs to gray-market research chemicals with no formal development at all. Dated, factual, no hype.

FDA-approved4
SemaglutideA
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Multiple large RCTs; SELECT 20% MACE reduction; MASH accelerated approval (Aug 2025). Tirzepatide beats it on weight loss.
ApprovedMetabolic
TirzepatideA
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Strongest dataset of any catalog peptide (SURPASS-CVOT n=13,299: non-inferior, NOT superior to dulaglutide; superiority P=0.09). +OSA approval Dec 2024.
ApprovedMetabolic
PT-141 (Bremelanotide)A
Preclinical
Phase 1
Phase 2
Phase 3
Approved
RECONNECT (n=1,267) met co-primaries with MODEST effect; did NOT increase satisfying sexual events. Men's use is Phase 2 at best / off-label.
ApprovedSexual health
TesamorelinA
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Approved for HIV-lipodystrophy only (~10-11% VAT reduction at 26 wks; '15-18%' overstates pivotal endpoints). Anti-aging use is extrapolation.
ApprovedGH secretagogue
In clinical trials2
RetatrutideB
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Late Phase 3 topline (company press release; not peer-reviewed). Dose-dependent dysesthesia (~21% high dose); cardiac arrhythmia signal in Phase 2.
InvestigationalMetabolic
Cagrilintide / CagriSemaB
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Multiple completed Phase 3 RCTs (REDEFINE 1/2 strong; REDEFINE 4 missed non-inferiority vs tirzepatide). Not approved.
InvestigationalMetabolic
Research / gray-market — no formal FDA pipeline12
DBPC-157Healing & recovery · animal-onlyRemoved from Cat 2 · pending PCACBGHK-CuCosmetic / skin · human trialsRemoved from Cat 2 · pending PCACDTB-500 (Thymosin beta-4 fragment)Healing & recovery · animal-onlyRemoved from Cat 2 · pending PCACBCJC-1295 / IpamorelinGH secretagogue · human trialsRemoved from Cat 2 · pending PCACBSermorelinGH secretagogue · human trialsResearch-use-only — gray marketDMOTS-cMetabolic · animal-onlyRemoved from Cat 2 · pending PCACEEpitalon (Epithalon)Longevity · mechanistic / anecdotalRemoved from Cat 2 · pending PCACBSelankCognitive · human trialsCategory 2 — restrictedBSemaxCognitive · human trialsRemoved from Cat 2 · pending PCACENAD+ (and precursors NMN/NR)Longevity · mechanistic / anecdotalResearch-use-only — gray marketBMelanotan IICosmetic / skin · human trialsBanned / prohibitedDKPVImmune / gut · animal-onlyRemoved from Cat 2 · pending PCAC

Regulatory status reflects the 2026 FDA docket (FDA-2025-N-6895) and moves often — re-verify before acting. Not medical or legal advice.